The FDA is currently reviewing new drug applications for market entry.
3 reports, 2 independent
Updated Sep 2
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA is currently reviewing new drug applications for market entry.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Kowa's New Drug Application (NDA) for drug K-911 was accepted by the FDA for review.Sub-event
FDA reviews new drug applications for market entry.1 source
Keep exploring
The entities involved
Related events
- FDA placed a clinical hold on the drug application submitted by Bright Minds Biosciences Inc.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- New FDA rule threatens the ability to import medicines.
- Policymakers are considering ways to influence the drug market, including potential changes to patent rights and the FDA approval process.
- Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.